Monkeypox Vaccines Coming to the Caribbean and Latin America

Denmark-based Bavarian Nordic A/S announced today an agreement with the Pan American Health Organization (PAHO) to facilitate access to the JYNNEOS® (MVA-BN) monkeypox/smallpox vaccine for countries in Latin America and the Caribbean.

Jynneos vaccines will be made available to those countries in September 2022 that participate in PAHO's Revolving Fund for Access to Vaccines.

Bavarian Nordic has delivered the vaccine to several undisclosed countries globally as part of their national biological preparedness.

Paul Chaplin, President, and CEO of Bavarian Nordic, stated in a press release on August 24, 2022, "... we are pleased to work with PAHO to ensure access to vaccines for its member states in the Americas."

"With the agreement, we have helped secure access to our vaccine in more than 70 countries globally, representing the vast majority of affected regions outside endemic areas."

"While the global supply is currently limited, we are working diligently to increase our manufacturing capacity and have taken steps to partner with other companies to produce more vaccines to help combat the outbreak rapidly."

The PAHO is the specialized health agency for the Americas, working with its 35 member countries throughout the region to improve and protect people's health.

MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, marketed as IMVANEX® in Europe, JYNNEOS® in the U.S., and IMVAMUNE® in Canada, is a non-replicating smallpox vaccine developed in collaboration with the U.S. government.

In addition to smallpox, the U.S. FDA, Health Canada, the U.K., and the European Commission have also approved the vaccine against monkeypox.

Additional monkeypox and smallpox vaccine deployment news is posted at PrecisionVaccinations.com/Monkeypox.

Today's Bavarian Nordic announcement was manually curated and translated for mobile readership.